Recent Analysts’ Ratings Changes for argenx (ARGX)

argenx (NASDAQ: ARGX) has recently received a number of price target changes and ratings updates:

• 11/21/2024 – argenx had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $675.00 price target on the stock, up previously from $646.00.
• 11/21/2024 – argenx had its price target raised by analysts at Evercore ISI from $675.00 to $706.00. They now have an “outperform” rating on the stock.
• 11/20/2024 – argenx had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $617.00 price target on the stock.
• 11/12/2024 – argenx was upgraded by analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating. They now have a $697.00 price target on the stock.
• 11/5/2024 – argenx was upgraded by analysts at Scotiabank from a “sector perform” rating to a “sector outperform” rating. They now have a $715.00 price target on the stock, up previously from $439.00.
• 11/4/2024 – argenx had its price target raised by analysts at JPMorgan Chase & Co. from $640.00 to $670.00. They now have an “overweight” rating on the stock.
• 11/1/2024 – argenx had its price target raised by analysts at Wells Fargo & Company from $547.00 to $639.00. They now have an “overweight” rating on the stock.
• 11/1/2024 – argenx had its price target raised by analysts at Piper Sandler from $553.00 to $620.00. They now have an “overweight” rating on the stock.
• 11/1/2024 – argenx had its price target raised by analysts at Oppenheimer Holdings Inc. from $560.00 to $646.00. They now have an “outperform” rating on the stock.
• 11/1/2024 – argenx was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.
• 11/1/2024 – argenx was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating. They now have a $650.00 price target on the stock, up previously from $515.00.
• 11/1/2024 – argenx had its price target raised by analysts at JMP Securities from $497.00 to $606.00. They now have a “market outperform” rating on the stock.
• 11/1/2024 – argenx was downgraded by analysts at Baird R W from a “strong-buy” rating to a “hold” rating.
• 11/1/2024 – argenx had its price target raised by analysts at Guggenheim from $585.00 to $665.00. They now have a “buy” rating on the stock.
• 11/1/2024 – argenx had its price target raised by analysts at HC Wainwright from $533.00 to $617.00. They now have a “buy” rating on the stock.
• 10/31/2024 – argenx had its price target raised by analysts at Truist Financial Co. from $540.00 to $660.00. They now have a “buy” rating on the stock.
• 10/17/2024 – argenx had its price target raised by analysts at Citigroup Inc. from $512.00 to $635.00. They now have a “buy” rating on the stock.
• 10/10/2024 – argenx had its “strong-buy” rating reaffirmed by analysts at Raymond James. They now have a $605.00 price target on the stock.
• 10/4/2024 – argenx was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a “buy” rating to a “hold” rating.

argenx Stock Performance

Shares of NASDAQ:ARGX traded up $0.94 during midday trading on Monday, hitting $617.49. 300,480 shares of the company’s stock traded hands, compared to its average volume of 310,016. The firm’s fifty day moving average price is $565.73 and its two-hundred day moving average price is $498.07. argenx SE has a twelve month low of $327.73 and a twelve month high of $622.32. The company has a market cap of $37.28 billion, a PE ratio of -701.69 and a beta of 0.61.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. During the same period in the prior year, the firm earned ($1.25) EPS. As a group, equities research analysts anticipate that argenx SE will post 2.2 EPS for the current fiscal year.

Hedge Funds Weigh In On argenx

A number of institutional investors have recently modified their holdings of the company. Cetera Advisors LLC bought a new position in shares of argenx during the 1st quarter worth about $419,000. DekaBank Deutsche Girozentrale lifted its holdings in argenx by 1.5% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 8,445 shares of the company’s stock worth $3,320,000 after buying an additional 128 shares in the last quarter. GAMMA Investing LLC increased its position in argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after purchasing an additional 40 shares during the period. Park Avenue Securities LLC raised its stake in shares of argenx by 7.2% during the second quarter. Park Avenue Securities LLC now owns 1,324 shares of the company’s stock worth $569,000 after buying an additional 89 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of argenx by 10.4% during the 2nd quarter. SG Americas Securities LLC now owns 2,999 shares of the company’s stock valued at $1,290,000 after acquiring an additional 283 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.